Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)
Sponsor: Brigham and Women's Hospital
Listed as NCT01762046, this PHASE1 trial focuses on Diabetes Mellitus, Type 2 and remains ongoing. Sponsored by Brigham and Women's Hospital, it has been updated 10 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Jun 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2024 [monthly]
Unknown Status PHASE1
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
- Broad Institute of MIT and Harvard
- Joslin Diabetes Center
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .